Abstract:The synthesis of a range of 3-hydroxy-4(1H)-pyridinones with potential for the chelation of iron(III) is described. The pK(a) values of respective ligands and the stability constants of their iron(III) complexes are presented, The distribution coefficient values of a range of 48 hydroxypyridinones and their corresponding iron(III) complexes between l-octanol and MOPS buffer (pH 7.4) are reported. The range of log D-complex values covers 7 orders of magnitude. The results suggest the existence of a biphasic relationship between the distribution coefficient values of the chelator and the corresponding iron(III) complexes. For ligands with a log D-ligand = -1, a linear relationship exists with a value of the slope 2.53, whereas with ligands with a log D-ligand < -1, a linear relationship exists with a slope of 0.49. The reduced slope for the more hydrophilic molecules of the series offers some advantage for this type of hydroxypyridinone as the distribution coefficients for such complexes do not change so rapidly with increasing ligand hydrophilicity. The ability of selected 3-hydroxypyridinones to facilitate the excretion of iron in bile was investigated in non-iron-overloaded, bile duct-cannulated rats and in a [Fe-59]ferritin-loaded rat model. Both systems compare the ability of chelators to remove iron from the liver, the prime target organ in thalassemia. The N-(hydroxyalkyl)-3-hydroxypyridin-4-ones are demonstrated to be orally active under the in vivo conditions adopted. Thus both 1-(hydroxyalkyl)- and 1-(carboxyalkyl)pyridinones are able to remove iron from the liver. Although 1-(carboxyalkyl)hydroxypyridinones are active, they do not demonstrate any clear advantage over Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one). Indeed 1-(hydroxyalkyl)hydroxypyridinones which are known to be rapidly converted to 1-(carboxyalkyl)hydroxypyridinones are also marginally superior to Deferiprone. In contrast, 2-ethyl-1-(2'-hydroxyethyl)-3-hyaroxypyridin-4-one, which is not metabolized to the corresponding (carboxyalkyl)hydroxypyridinone, was found to be superior to Deferiprone and therefore deserves further consideration as an orally active iron chelator with potential for the treatment of iron overload associated with transfusion-dependent thalassemia.

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations

A Randomized, Controlled, Open Label Non-Inferiority Trial of Intravenous Ferric Carboxymaltose Versus Iron Sucrose in Patients with Iron Deficiency Anemia in China.

An Analytical Method for Determination of Total Iron in Pharmaceuticalgrade Intravenous Iron Colloidal Complexes by Redox-Potentiometry

Analysis of the Effect of Iron Dextran Oral Liquid on Pediatric Nutritional Iron Deficiency Anemia

Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation

A comprehensive study of intravenous iron-carbohydrate nanomedicines: From synthesis methodology to physicochemical and pharmaceutical characterization

Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD

Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake

Ferrous iron content of intravenous iron formulations

Iron bioavailability from commercially available iron supplements

An analytical method for the quantitative determination of iron ion chelating capacity: development and validation

Physicochemical and toxicological characterization of a new generic iron sucrose preparation

Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver.

Case studies: iron

Dissimilar ferric derisomaltose formulations - In vitro comparisons between an originator and its intended similars

Synthesis, Physicochemical Properties, and Evaluation of<i>N</i>-Substituted-2-alkyl-3-hydroxy-4(1<i>H</i>)-pyridinones<sup>†</sup>

Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements

Comparative Evaluation of Intestinal Absorption and Functional Value of Iron Dietary Supplements and Drug with Different Delivery Systems

Physicochemical and structural characterization of iron-sucrose formulations: a comparative study

The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study

An Electrolytic Elemental Iron Powder Effectively Regenerates Hemoglobin in Anemic Rats and Is Relatively Well Absorbed When Compared to Ferrous Sulfate Monohydrate